Vita Genomics, Inc., centered in Taiwan and China, aims to be
a premier genomics-based biotechnological and biopharmaceutical company
in the AsiaˇVPacific region. The company focuses on conducting pharmacogenomics research,
in vitro diagnosis product development, and specialty contract research services in both
genomics and pharmacogenomics fields. We are now initiating a drug rescue program designed
to resurrect drugs that have failed in the previous clinical trials owing to low efficacies.
This program applies pharmacogenomics approaches using biomarkers to screen subsets of patients
who may respond better or avoid adverse responses to the test drugs. Vita Genomics, Inc.
has envisioned itself as an important player in the healthcare industry offering advanced
molecular diagnostic products and services, revolutionizing the drug-development process and
providing pharmacogenomic solutions. Please see
the list of publications
and the company profile of Vita Genomics
(Pharmacogenomics, June 2007, Vol. 8, No. 6, Pages 669-673).
Vita Genomics, founded in March 2001, has established
its headquarter in Taiwan, a marketing office in California,
USA, and a wholly owned subsidiary GeneCore in Shanghai,
China. Vita Genomics has envisioned itself to be an
important player in the healthcare industry by offering
advanced and targeted molecular diagnostic products
and services, providing more efficient and safer medical
solutions, improving the drug development process, and
lowering the overall healthcare cost through the pharmacogenomics
Vita Genomics has already built up strong relationships
with research institutions and medical organizations
throughout Taiwan and China. We are constantly looking
for pharmaceutical partners who can benefit from identifying
patients for drug responsiveness prior to treatments,
partners who would fund expanded pharmacogenomics studies
that will enable us to validate the responsiveness of
all significant genotypes, and partners who would co-develop
DNA-based molecular diagnostic products.
Vita Genomics is an active participant
in modernizing Taiwan healthcare system. We are establishing
the infrastructure needed to add the molecular profile
information to the healthcare integrated circuit (IC)
card. This is a first step in creating personalized
medicine in the future. In addition, Vita Genomics can
act as the conduit between the western world and China
because we have already established a beachhead in Shanghai.
Vita Genomics follows the high standards of US FDA guidelines
in collecting samples in conducting research and clinical
studies.Vita Genomics concentrates on the elucidation
of the genes and pathways involved in various diseases
and on the drug responsiveness of patients in an attempt
to improve the healthcare system.